A phase I/II open label study of the safely and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis

Arthur F. Kavanaugh, Laurie S. Davis, Rita I. Jain, Lisa A. Nichols, Steven H. Norris, Peter E. Lipsky

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Objective. Previous work suggested the potential utility of therapy with a monoclonal antibody (Mab) to intercellular adhesion molecule-1 (ICAM-1; CD54) in patients with longstanding rheumatoid arthritis (RA). Immunomodulatory interventions, including adhesion receptor directed therapies, might be expected to have greater efficacy in patients with less established or less aggressive disease. Therefore, we assessed the efficacy and safety of an anti-ICAM-1 Mab in patients with early RA. Methods. An open label study of a 5 day infusion of an anti-ICAM-1 Mab in 10 patients with early or indolent RA was conducted. These patients were defined as having previously used ≤ 1 disease modifying antirheumatic drug. Results. Based on composite criteria, 7/10 patients had a marked or moderate response to therapy at one month of followup. Clinical benefit was sustained through 2 months for 5/10 patients and 3/10 had extended benefit (11, 8, and > 7 months). Clinical benefit was more likely to be obtained in patients with subacute onset of disease than in those with a fulminant onset. Conclusion. A single course of therapy with an anti-ICAM-1 Mab was associated with clinical improvement in a group of patients with early or indolent RA to an extent apparently greater than previously observed in patients with longstanding, aggressive RA.

Original languageEnglish (US)
Pages (from-to)1338-1344
Number of pages7
JournalJournal of Rheumatology
Volume23
Issue number8
StatePublished - 1996

Fingerprint

Intercellular Adhesion Molecule-1
Rheumatoid Arthritis
Monoclonal Antibodies
Antirheumatic Agents
Therapeutics
Safety

Keywords

  • Adhesion receptors
  • Intercellular adhesion molecule-1
  • Monoclonal antibody
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

A phase I/II open label study of the safely and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. / Kavanaugh, Arthur F.; Davis, Laurie S.; Jain, Rita I.; Nichols, Lisa A.; Norris, Steven H.; Lipsky, Peter E.

In: Journal of Rheumatology, Vol. 23, No. 8, 1996, p. 1338-1344.

Research output: Contribution to journalArticle

Kavanaugh, Arthur F. ; Davis, Laurie S. ; Jain, Rita I. ; Nichols, Lisa A. ; Norris, Steven H. ; Lipsky, Peter E. / A phase I/II open label study of the safely and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. In: Journal of Rheumatology. 1996 ; Vol. 23, No. 8. pp. 1338-1344.
@article{822ed92827b142b58609beca0ee634f6,
title = "A phase I/II open label study of the safely and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis",
abstract = "Objective. Previous work suggested the potential utility of therapy with a monoclonal antibody (Mab) to intercellular adhesion molecule-1 (ICAM-1; CD54) in patients with longstanding rheumatoid arthritis (RA). Immunomodulatory interventions, including adhesion receptor directed therapies, might be expected to have greater efficacy in patients with less established or less aggressive disease. Therefore, we assessed the efficacy and safety of an anti-ICAM-1 Mab in patients with early RA. Methods. An open label study of a 5 day infusion of an anti-ICAM-1 Mab in 10 patients with early or indolent RA was conducted. These patients were defined as having previously used ≤ 1 disease modifying antirheumatic drug. Results. Based on composite criteria, 7/10 patients had a marked or moderate response to therapy at one month of followup. Clinical benefit was sustained through 2 months for 5/10 patients and 3/10 had extended benefit (11, 8, and > 7 months). Clinical benefit was more likely to be obtained in patients with subacute onset of disease than in those with a fulminant onset. Conclusion. A single course of therapy with an anti-ICAM-1 Mab was associated with clinical improvement in a group of patients with early or indolent RA to an extent apparently greater than previously observed in patients with longstanding, aggressive RA.",
keywords = "Adhesion receptors, Intercellular adhesion molecule-1, Monoclonal antibody, Rheumatoid arthritis",
author = "Kavanaugh, {Arthur F.} and Davis, {Laurie S.} and Jain, {Rita I.} and Nichols, {Lisa A.} and Norris, {Steven H.} and Lipsky, {Peter E.}",
year = "1996",
language = "English (US)",
volume = "23",
pages = "1338--1344",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "8",

}

TY - JOUR

T1 - A phase I/II open label study of the safely and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis

AU - Kavanaugh, Arthur F.

AU - Davis, Laurie S.

AU - Jain, Rita I.

AU - Nichols, Lisa A.

AU - Norris, Steven H.

AU - Lipsky, Peter E.

PY - 1996

Y1 - 1996

N2 - Objective. Previous work suggested the potential utility of therapy with a monoclonal antibody (Mab) to intercellular adhesion molecule-1 (ICAM-1; CD54) in patients with longstanding rheumatoid arthritis (RA). Immunomodulatory interventions, including adhesion receptor directed therapies, might be expected to have greater efficacy in patients with less established or less aggressive disease. Therefore, we assessed the efficacy and safety of an anti-ICAM-1 Mab in patients with early RA. Methods. An open label study of a 5 day infusion of an anti-ICAM-1 Mab in 10 patients with early or indolent RA was conducted. These patients were defined as having previously used ≤ 1 disease modifying antirheumatic drug. Results. Based on composite criteria, 7/10 patients had a marked or moderate response to therapy at one month of followup. Clinical benefit was sustained through 2 months for 5/10 patients and 3/10 had extended benefit (11, 8, and > 7 months). Clinical benefit was more likely to be obtained in patients with subacute onset of disease than in those with a fulminant onset. Conclusion. A single course of therapy with an anti-ICAM-1 Mab was associated with clinical improvement in a group of patients with early or indolent RA to an extent apparently greater than previously observed in patients with longstanding, aggressive RA.

AB - Objective. Previous work suggested the potential utility of therapy with a monoclonal antibody (Mab) to intercellular adhesion molecule-1 (ICAM-1; CD54) in patients with longstanding rheumatoid arthritis (RA). Immunomodulatory interventions, including adhesion receptor directed therapies, might be expected to have greater efficacy in patients with less established or less aggressive disease. Therefore, we assessed the efficacy and safety of an anti-ICAM-1 Mab in patients with early RA. Methods. An open label study of a 5 day infusion of an anti-ICAM-1 Mab in 10 patients with early or indolent RA was conducted. These patients were defined as having previously used ≤ 1 disease modifying antirheumatic drug. Results. Based on composite criteria, 7/10 patients had a marked or moderate response to therapy at one month of followup. Clinical benefit was sustained through 2 months for 5/10 patients and 3/10 had extended benefit (11, 8, and > 7 months). Clinical benefit was more likely to be obtained in patients with subacute onset of disease than in those with a fulminant onset. Conclusion. A single course of therapy with an anti-ICAM-1 Mab was associated with clinical improvement in a group of patients with early or indolent RA to an extent apparently greater than previously observed in patients with longstanding, aggressive RA.

KW - Adhesion receptors

KW - Intercellular adhesion molecule-1

KW - Monoclonal antibody

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0029739255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029739255&partnerID=8YFLogxK

M3 - Article

C2 - 8856611

AN - SCOPUS:0029739255

VL - 23

SP - 1338

EP - 1344

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 8

ER -